This section offers a closer look to TransQST activities through interviews to project partners. These interviews also have the aim to provide deeper insights into the application and applicability of the project results, while introducing the members of the teams working behind the scenes.


 

Open post

Synapse Research Management Partners

From left to right: Inari Soininen and Mery Loor.

What is SYNAPSE’s main field of specialization? Synapse is a firm specialized in the high-quality management of complex research and development projects in the biomedical sector. In fact, we have close to 15 years of experience preparing and managing research projects in the healthcare sector funded by European programs such as IMI, H2020 or the […]

Read moreMore Tag
Open post

Eli Lilly and Company Ltd (Eli-Lilly)

Derek Leishman, Senior Research Fellow at Eli Lilly.

What is Eli-Lilly´s main field of specialization? Lilly is a large pharmaceutical company focused on human medicinal products.  We are active in most therapeutic areas. How has your company been involved in the project? Lilly has been directly involved in the organ work packages, especially cardiovascular, liver and GI.  We have been EFPIA leads in […]

Read moreMore Tag
Open post

UM (Universiteit Maastricht)

From left to right: Theo de Kok, Daniela Rodriguez, Danyel Jennen.

What is UM’s main focus? At the department of Toxicogenomics of Maastricht University (UM) we have a multidisciplinary team of (cell) biologists, chemists, geneticists, toxicologists and bioinformaticians that is working in close collaboration to establish the biological impact of exposures to potentially toxic compounds and to develop safe therapeutic strategies for genetic and non-genetic diseases. […]

Read moreMore Tag
Open post

IRIS (Institut de Recherches Internationales Servier)

Image from left to right: Stéphanie Billiald and Sylvain Fouliard.

Contributors: Sylvain Fouliard Stéphanie Billiald Nicolas Sajot What are your main research interests? Within Translational Medicine, the non-Clinical Safety and the Quantitative Pharmacology groups aim at supporting the development of new medications and treatment modalities to improve patients’ lives. Our mission in Translational Medicine is to effectively bridge discovery, preclinical and clinical phases thereby improving […]

Read moreMore Tag
Open post

IFADO

The IFADO team.

What is IFADO’s main focus? Our passion is liver physiology, hepatotoxicity and functional imaging. How has participating in TransQST impacted your company? We had the chance to find partners with common interests and complementary technologies; this allowed us to establish exciting collaborations. What challenges has IFADO faced across the project? What are your main achievements […]

Read moreMore Tag

Posts navigation

1 2 3